Skip to main content
. 2018 Apr 30;16(2):315–318. doi: 10.5217/ir.2018.16.2.315

Table 2. Details of Methotrexate Drug Use.

Variable Value (n=10)
Age at initiation of MTX (yr) 52.3±9.7
Disease duration at initiation of MTX (yr) 6.7±5.5
Initial administration route
 Parenteral 2 (20.0)
 Oral 8 (80.0)
MTX dose (mg/wk) 13.0±3.3
MTX regimen
 MTX monotherapy 4 (40.0)
 MTX with anti-TNF-α 6 (60.0)
Concomitant medication
 5-ASA 9 (90.0)
 Colchicine 4 (40.0)
 Corticosteroid 9 (90.0)
 Anti-TNF-α
  Infliximab 0
  Adalimumab 6 (60.0)
 Opioid 3 (30.0)
 NSAID 6 (60.0)
 Antibiotics 4 (40.0)
Indication for MTX
 Thiopurine intolerance 1 (10.0)
 Thiopurine ineffectiveness 0
 Failure of monotherapy anti-TNF-α 6 (60.0)
 Corticosteroid dependence 3 (30.0)
Reason discontinue (n=4)
 Clinical ineffectiveness 3 (75.0)
 Self-interruption 1 (25.0)

Values are presented as mean±SD or number (%).

MTX, methotrexate; TNF, tumor necrosis factor; ASA, aminosalicylic acid.